Learn about agents that target pathways in solid tumors other than PD-1/PD-L1
This activity is intended for hematologists/oncologists, nurses, and pharmacists.
The goal of this activity is to improve knowledge regarding immunotherapy pathways beyond programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1), and data for agents that target these pathways.
- Have increased knowledge regarding the common strategies and pathways beyond PD-(L)1 that cancer cells harness to avoid detection by the immune system
- Have increased knowledge regarding the mechanisms of action (MOAs) of emerging cancer immunotherapies
- Have increased knowledge regarding the scientific rationale for evaluating and integrating cancer immunotherapy throughout the continuum of care for patients with cancer
Approximate Time to Complete: 30 minutes
Credit Available: Dec. 26, 2019 - Dec. 26, 2020
Developed through a partnership between SITC and Medscape.